ScreenerHero

DAREDare Bioscience, Inc.

NAS · US · Healthcare · Biotechnology · darebioscience.com
0.8199USD-0.55%Mkt Cap: 15.89M $P/E: —

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript

Net loss narrowed to $3 million as nondilutive funding offset R&D costs.

Motley Fool
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ...

Dare Bioscience transitions to a commercial-stage company with the launch of FloraSync LF5, while advancing its women's health pipeline and securing non-dilutive funding.

GuruFocus.com
Daré Bioscience, Inc. Q2 2026 Earnings Call Summary

Moby summary of Daré Bioscience, Inc.'s Q2 2026 earnings call

Moby
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +39.39% and +1,775.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -16.67% and -30.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks